This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.00614-06v1 44/11/4085    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Menozzi, M. G. Articles by Fahr, A.-M. Search for Related Content PubMed PubMed Citation Articles by Menozzi, M. G. Articles by Fahr, A.-M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2006, p. 4085-4094, Vol. 44, No. 11
0095-1137/06/$08.00+0     doi:10.1128/JCM.00614-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Two-Center Collaborative Evaluation of Performance of the BD Phoenix Automated Microbiology System for Identification and Antimicrobial Susceptibility Testing of Gram-Negative Bacteria

Section of Microbiology, Department of Pathology and Laboratory Medicine, University of Parma, I-43100 Parma, Italy,¹ Department of Microbiology, Laboratory Group Heidelberg, D-69126 Heidelberg, Germany²

Received 22 March 2006/ Returned for modification 2 May 2006/ Accepted 14 September 2006

The performance of the BD Phoenix Automated Microbiology System (BD Diagnostic Systems, Sparks, MD) was assessed for identification (ID) and antimicrobial susceptibility testing (AST) of the majority of clinically encountered bacterial isolates in a European collaborative two-center trial. A total of 494 bacterial isolates including various species of the Enterobacteriaceae and 110 nonfermentative gram-negative bacteria were investigated: of these, 385 were single patient isolates, and 109 were challenge strains tested at one center. The performance of the Phoenix extended-spectrum ß-lactamase (ESBL) test was also evaluated for 203 strains of Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca included in the study. Forty-two antimicrobial drugs were tested, including members of the following drug classes: aminoglycosides, ß-lactam antibiotics, ß-lactam/ß-lactamase inhibitors, carbapenems, cephems, monobactams, folate antagonists, quinolones, and others. Phoenix system ID results were compared to those of the laboratories' routine ID systems (API 20E and API CHE, ATB ID32E, ID32GN, and VITEK 2 [bioMérieux, Marcy l'Etoile, France]); Phoenix AST results were compared to those of frozen standard broth microdilution (SBM) panels according to NCCLS (now CLSI) guidelines (NCCLS document M100-S9, approved standard M7-A4). Discrepant results were repeated in duplicate. Concordant IDs of 98.4 and 99.1% were observed for the Enterobacteriaceae and the nonfermentative group, respectively. For AST results, the overall essential agreement was 94.2%; the category agreement was 97.3%; and the very major error rate, major error rate, and minor error rate were 1.6, 0.6, and 1.9%, respectively. In terms of ESBL detection, Phoenix results were 98.5% concordant with those of the reference system, with 98.0% sensitivity and 98.7% specificity. In conclusion, the Phoenix ID results showed high agreement with results of the systems to which they were being compared: the AST performance was highly equivalent to that of the SBM reference method, and the system proved to be very accurate for the detection of ESBL producers.

Published ahead of print on 27 September 2006.

This article has been cited by other articles:

• Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]